Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression of mRNA and lncRNA in human oral cancer cell SCC25 treated with tunicamycin

ABSTRACT: ER stress induced mRNA and lncRNA change has not been fully characterised yet in human cells. We used HTA 2.0 microarry to explore this topic.

ORGANISM(S): Homo sapiens

PROVIDER: GSE146505 | GEO | 2023/01/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Aberrant lncRNA expression profiles in OSCC tissues compared with paired normal oral mucosa

Project description:Hypoxic microenvironment plays important roles in the progression of solid tumors including oral squamous cell carcinoma (OSCC). Long noncoding RNAs (lncRNAs) have gained much attention in the past few years. However, it is not clear whether lncRNAs could regulate hypoxia-adaptation of OSCC, and which lncRNAs participate in this process. Using an lncRNA microarray, we analyzed the aberrant lncRNA expression profiles in OSCC tissues compared with paired normal oral mucosa as well as in hypoxic OSCC cells compared with normoxic OSCC cells. Our data revealed 2053 differentially expressed (Fold Change >= 2.0, P-value <= 0.05) lncRNAs, among which 934 lncRNAs were significantly up-regulated and 1119 lncRNAs were down-regulated in OSCC compared with paired normal mucosa. Six OSCC tissues and paired normal oral mucosa were obtained from 6 patients with OSCC. LncRNA expression profiles were evaluated by an Agilent Human LncRNA Array v3.0 (8 x 60K, Arraystar).

2016-07-26 | E-GEOD-84805 | biostudies-arrayexpress

Aberrant lncRNA expression profiles in OSCC tissues compared with paired normal oral mucosa

2016-07-26 | GSE84805 | GEO

Expression of LncRNA in oral squamous carcinoma

Project description:To elucidate the biological functions of lncRNA DUXAP9 in the process of oral squamous carcinogenesis and progression, and to evaluate its potential as a clinical predictive biomarker and therapeutic target,and toinvestigate the mechanism on how lncRNA DUXAP9 regulates EZH2,we screened lncRNAs differentially expressed in OSCC

2022-10-17 | GSE215767 | GEO

Exon Level Expression Profiling:HTA 2.0 array

Project description:Exon Level Expression Profiling:HTA 2.0 array

| PRJNA814287 | ENA

SAM treatment of CRC cell lines

Project description:whole-transcriptom analysis of HT-29 and SW480 cells by HTA 2.0 microarray

2020-09-09 | GSE152870 | GEO

Transcriptome Expression Data from Resected Operative Ileal Mucosa Specimens in a cohort of patients with Crohns Disease

Project description:Affymetrix human whole transcriptome array (HTA 2.0) completed on patients with Crohn's disease undergoing their first ileocolic resection

2018-08-21 | GSE118754 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD4+ cells, exon level]

Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD4+ cells, preprocessed according to the exon level workflow.

2015-09-19 | GSE73080 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD4+ cells, gene level]

2015-09-19 | GSE73079 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD8+ cells, exon level]

Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD8+ cells, preprocessed according to the exon level workflow.

2015-09-19 | GSE73172 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD8+ cells, gene level]

Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD8+ cells, preprocessed according to the gene level workflow.

2015-09-19 | GSE73081 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data